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Introduction
Over the last two decades, the range of oncological treatments have largely broadened, and considerable progress has been made concerning the efficacy of anticancer treatments [1] . However, during the same period, the aggressiveness of cancer care near the end of life has emerged as a growing concern [2, 3] . Many studies reported a significant increase in the use of chemotherapy in the final weeks of life [4] [5] [6] [7] . The American Society of Clinical Oncology recommends to avoid the use of chemotherapy near the end of life due to the absence of evidence supporting its clinical value [8] . Furthermore, the risk of adverse events related to chemotherapy is amplified by malnutrition, immunosuppression and sarcopenia, with an increased probability of acute toxicity and a negative impact on the patients' quality of life [9] . Chemotherapy in patients with poor performance status is also associated with higher odds of dying in acute care hospitals and with less frequent hospice use, which can both be detrimental to the patients' wellbeing [10, 11] . The financial impact of active treatments near the end of life has also come under great scrutiny [12, 13] .
Prior studies reported rates of chemotherapy use ranging from 5% to 55% in the last month before death [14] [15] [16] . Many factors have been found to be associated with chemotherapy near the end of life, including sociodemographic characteristics, clinical parameters and environmental factors (e.g. type of hospital, specialty of the physician, geographical inequalities, funding scheme). However, these studies were often mono-center, dedicated to a single tumor site or a specific subgroup of patients or institutions. There is therefore a need for a more precise examination of the factors associated with chemotherapy at the end of life, in order to identify situations of potential over-treatment.
This study aimed to examine patient-level, tumor-related and facility-level factors associated with the use of chemotherapy in the final months before death. We hypothesized that, while controlling for potential confounders, having a chemosensitive tumor and being treated in a tertiary care facility (university hospital or comprehensive cancer center) were associated with higher odds of receiving chemotherapy near the end of life.
Methods

Study design and data source
We assembled a retrospective cohort of hospital cancer decedents, using data from the French national hospital register (PMSI). This register, which covers all hospitals in France, collects healthcare claims for every inpatient admissions and outpatient visits, regardless of the ownership of the facility and of the patients' insurance status. Electronic records were linked to recreate the patients' history over the course of the last 3 months before death. This study was reviewed and approved by the French National Dataprotection Agency (DE/2014/112).
Study population
Adults aged 20 years or older who died in hospitals between 1 January 2010 and 31 December 2013 were included if they were diagnosed with a solid cancer at a metastatic stage, or with a brain or a liver cancer (regardless of the stage of the disease as these tumors are rarely metastatic and usually lethal at locoregional stages). Cancer diagnoses were identified through International Classification of Diseases, 10th revision (ICD-10) codes recorded as main or secondary diagnoses during the last hospital stay. To limit heterogeneity in the study population, decedents with hematological malignancies or with multiple primary tumor sites were excluded. Given the nature of the register, patients who died in the community or in nursing homes could not be included.
Outcomes
We assessed the use of chemotherapy over the course of the last 3 months of life, defined as the administration of at least one dose of chemotherapy (including oral targeted therapies) during an inpatient hospitalization, outpatient visits or through a hospital-at-home service. We also examined the initiation of chemotherapy during the last month of life of patients who were not treated with chemotherapy during their third and second last months of life (i.e. patients who started or resumed a chemotherapy regimen during the last month before death). Chemotherapy regimen delivered as part of a clinical trial were not included.
Variable definitions: patient-, tumor-and facility-level characteristics Patients sex, age, and primary malignancy were retrieved from the national hospital register. We evaluated the number of Charlson comorbidities (computed as the number of chronic diseases included in the Charlson Comorbidity Index) reported as main or secondary diagnoses during the last 3 months before death. Evidence from the published literature prior to 2010 was compiled to extract the characteristics of 26 tumor sites at the metastatic stage: the expected tumor chemosensitivity (using the definition suggested by Kao et al. [14] of a response rate to standard first-line metastatic chemotherapy >30%), the expected median overall survival, and the release of new drugs between 2005 and 2010 that showed significant improvement in overall survival. Details about the characterization and classification of tumor sites are presented in sup plementary Table S1 , available at Annals of Oncology online. Finally, we derived several facility-level characteristics: category of hospital, annual volume of chemotherapy, annual number of in-hospital deaths and the existence of a palliative care unit within the facility. In France, palliative care units are inpatient services fully dedicated to the care of palliative patients with complex needs.
Statistical analysis
The characteristics of the study population were reported using both absolute values and percentages, the differences between subgroups being assessed with the Pearson's chi-squared test with a level of significance set at P < 0.001. Outcome measures were not only reported for the overall study population, but were also stratified by patient-and facility-level characteristics. To examine the factors associated with the use of chemotherapy during the last month before death, we computed two multivariable logistic regression models: the first included only patient-level characteristics as explanatory variables, while the second model included both patient-and facility-level characteristics. We also performed a series of multivariable analyses to gain a better insight on the association between the tumors' therapeutic characteristics and the likelihood of receiving chemotherapy during the last month before death. Since sufficient evidence from the literature could be retrieved for only 26 tumor sites, these analyses were performed on a subset of the total study population. Adjusted odds ratios (OR) were reported with their 95% confidence intervals (CI). All statistical analyses were performed using SAS JMP 12.1.0 (SAS Institute, Inc.).
Results
Characteristics of the study population
Between January 2010 and December 2013, 516 244 cancer patients died in hospitals. Among them, 236 398 patients did not meet our inclusion criteria and were therefore excluded from the analyses (Figure 1) . The study population consisted of 279 846 patients, of whom 58% were men, and 39.5% were aged 75 years. Characteristics of cancer decedents are reported in Table 1 .
Frequency of chemotherapy use over the course of the last 3 months of life A total of 39.1% of patients received chemotherapy during the last 3 months before death, 19.5% during the last month, 11.3% during the last 2 weeks and 7.0% during the last week. The decline in the use of chemotherapy was modest between the third and the second months before death but intensified as death approached, with considerable variation according to the age and the number of Charlson comorbidities of the decedents ( Figure 2 ). More detailed results about patient's characteristics, tumor sites and hospital types are presented in supplementary Table S2 , available at Annals of Oncology online.
Factors associated with chemotherapy use during the last month of life
While controlling for patient-and facility-level characteristics, male gender, younger age and a low number of comorbidities were associated with an increased likelihood of receiving chemotherapy in the last month of life. As shown in Table 2 , we also found significant discrepancies between the different tumor localizations, with chemotherapy rate in the last month ranging from 10-11% (male genital organs and thyroid cancer) to 25-26% (breast, gynecological, head and neck cancer). These differences between tumor sites remained after adjustment. The rate of chemotherapy in the last month of life varied from 9.4% in patients who died in small public hospitals to 19.7% in patients who died in university hospitals, 24.6% in private for-profit clinics and to 34% in comprehensive cancer centers. While controlling for patient-level confounding factors, patients who died in comprehensive cancer centers and private for profit clinics were, respectively, 43% and 40% more likely to receive chemotherapy during the last month before death than patients who died in university hospitals. Similarly, as reported in Table 2 , patients treated in a hospital without a palliative care unit and with a higher annual volume of chemotherapy were more likely to receive chemotherapy. We found a positive facility-level correlation between the annual volume of chemotherapy and the rate of chemotherapy use near the end of life. However, we also found that irrespective of the annual volume of chemotherapy, comprehensive cancer centers had higher rates of chemotherapy near the end of life than university hospitals (supplementary Figure S1 , available at Annals of Oncology online).
Starting or resuming chemotherapy in the last month
Among 182 406 patients who did not receive chemotherapy during the third and second months before death, 11 980 (6.6%) started or resumed a chemotherapy regimen during their last month of life. The frequency by tumor localization was very similar to the global chemotherapy use. As in previous analysis, male gender, young age, low number of comorbidities, absence of palliative care unit, high annual volume of chemotherapy, and dying in comprehensive cancer centers or private hospitals were positively associated with higher odds of starting or resuming a chemotherapy regimen (supplementary Table S3 , available at Annals of Oncology online).
Association between tumor chemosensitivity and use of chemotherapy in the last month of life
We performed a series of sub-analyses for the 182 938 patients who died from 26 tumor sites for which there was sufficient evidence regarding the degree of chemosensitivity, defined as the response rate to standard first-line chemotherapy for metastatic disease (sup plementary Table S1 , available at Annals of Oncology online). While controlling for both patient-and facility-level characteristics, patients with chemosensitive tumors were found to be more likely to receive chemotherapy in the last month before death (OR ¼ 1.21, 95% CI ¼ 1.18-1.25) than patients who died from non-chemosensitive tumors. As presented in Figure 3 , this overall association was found to be constant across gender, age, comorbidity and hospital subgroups, although not significant for patients aged 90 years and patients who died in small public hospitals. Tumor chemosensitivity was also found to be associated with higher odds of starting or resuming a chemotherapy regimen during the last month before death (supplementary Figure S2 , available at Annals of Oncology online). With the exception of testis and ovary tumors, most tumor sites show no evident association between their level of chemosensitivity and the proportion of decedents who received chemotherapy near the end of life (supplementary Figure S3 , available at Annals of Oncology online).
As shown in Table 3 , patients who died from metastatic tumors with an expected median overall survival >24 months were more likely to receive chemotherapy during the last month of life than patients with an expected survival of <12 months (OR ¼
Discussion
We analyzed a large cohort of hospitalized patients with metastatic solid cancer who died between 2010 and 2013. Three types of factors were found to be independently associated with a greater likelihood of receiving chemotherapy close to death: patients' characteristics (male sex, young age and low number of chronic comorbidities), tumor-related parameters (chemosensitivity, expected survival and existence of new therapeutic options) and facility-level factors (private clinics, comprehensive cancer centers, high-volume of chemotherapy and lack of palliative care unit).
With chemotherapy rates of 19.5% during the last month and 11.3% during the last 2 weeks of life, our findings remain within the range of results reported previously in the literature-between the low rates of Ontario [5] and the high rates of Asian countries [10, 17] , and comparable although somewhat greater than those observed in the United States [2, 18] . Interestingly, the rates of chemotherapy in the final month before death were found to be lower in other European countries: 16% in Belgium, 13% in Germany, 15% in the Netherland and 6% in Norway [15] . However, comparing rates of chemotherapy reported over the course of almost two decades is difficult, as the recent development of targeted therapies has broadened the therapeutic landscape of malignancies previously known for their dreadful prognosis.
We hypothesized that high rates of chemotherapy use near the end of life were driven by the tumors' therapeutic characteristics, in particular their supposed chemosensitivity. Defining chemosensitivity remains challenging without patient-level data documenting the histology and the molecular biology of the malignancies. Kao et al. [14] suggested to consider tumors as chemosensitive if their response rate in standard first-line chemotherapy was superior to 30%. Using this definition, we found that reputedly chemosensitive tumors were associated with higher rates of chemotherapy use in the last month of life. This result was however mostly propelled by testis and ovary cancers, and we found surprisingly high rates of chemotherapy in patients with metastatic pancreatic cancer, melanoma, mesothelioma, soft tissue sarcoma or biliary tract-all known for their poor response rate to chemotherapy. In fact, we found no evident pattern between the expected chemosensitivity of different cancers and the likelihood for patients to receive chemotherapy close to death. Our findings therefore add up to the contradictory results reported previously, with two studies suggesting a positive association between the level of chemosensitivity and the use of chemotherapy near the end of life [19, 20] and two studies reporting no association [18, 21] . One should however bear in mind that methods estimating chemosensitivity based on first-line standard treatments have important limitations since chemotherapy administered in the final month of life is often well beyond first line. The use of validated prognostic scores to identify patients that are the least likely to benefit from chemotherapy would be an important step to reduce its potential overuse close to death [22] [23] [24] . The decision to initiate, continue or discontinue treatments at the end of life is often fueled by the comparison between three parameters: the patient's remaining life expectancy, the expected outcome of an additional line of chemotherapy in terms of survival and quality of life, and the time-until-benefit of the treatment [25] . Our study shows that patients who died from cancers with a median overall survival of >24 months were more likely to receive chemotherapy near the end of life. We hypothesize that, in these situations, the belief of a good-prognosis and the trust in the effectiveness of treatments may lead to over-realistic expectations as death approaches [26, 27] . This 'therapeutic illusion' [28] on the part of patients, families and doctors leads not only to prescribing potentially unnecessary and costly drug treatments, but also to increase the risk of potentially harmful effects. A recent prospective study inthe United States reported that the quality of life near death of patients with end-stage cancer was not improved by palliative chemotherapy, even among patients with good performance status [9] .
Rates of chemotherapy near the end of life varied significantly according to hospital-level characteristics. As described in previous studies, we found that patients who died in private for-profit facilities were significantly more likely to receive chemotherapy in the final month of life than patients who died in public hospitals [29] . It should be noted although 30% of all chemotherapy cycles in France occur in private for-profit clinics, little has been done to promote advance care planning and to improve supportive care in these facilities. Tertiary hospitals with high annual volumes of chemotherapy also reported greater-than-average rates of chemotherapy near the end of life. These discrepancies might be partly explained by stronger desire for aggressive treatments among patients treated in Comprehensive Cancer Centers and University Hospitals, often able to offer therapeutic alternatives that are unavailable in other types of facility [30] . The strong cultural focus on chemotherapy, the highly specialized profile of oncologists working in these high-volume centers and the lack of integration of multidisciplinary palliative care teams in the daily practice might also contribute a great deal to the aggressiveness of care near the end of life.
The use of chemotherapy close to death is part of a larger pattern of end-of-life care in France, where the proportion of cancer deaths occurring in hospitals is one of the highest in Europe [31] . Our findings are symptomatic of an increasingly pressing societal demand for the medicalization of the final years and months of life. Better advance care planning, enhanced access to palliative care consultations, evidence-based clinical guidelines and improved patient-physician communication are needed to reduce the inadequate escalation of care intensity near the end of life.
This study comes with several methodological limitations. First, we could only include patients who died in hospitals, thus restricting the generalizability of our results to individuals who died at home or in nursing homes. The rate of chemotherapy at the end of life is indeed most likely higher among hospitalized decedents than among those who died in the community. However, it should be noted that in France 77% of cancer patients die in hospitals [31] and that we included all adult patients regardless of their healthcare insurance status, in both public and private hospital facilities. Second, due to the nature of the data source we had no access to information regarding performance and nutritional status, tumors' histological sub-types, and number of previous chemotherapy regimens. Also, as this study was based on hospital activity data, treatments delivered by community pharmacies were not included. Treatments delivered as part of a clinical trial were also not accounted for in this study, most likely leading to some degree of underestimation of the actual use of chemotherapy in university hospitals and comprehensive cancer centers. Third, we cannot exclude some declaration bias or coding errors in the national hospital register, although the quality of Adjusted on patient-level characteristics and facility-level variables (category of hospital, number of chemotherapy encounters and existence of a palliative care unit). OR, odds ratio; CI, confidence interval. metastatic or locally lethal cancers (e.g. liver and brain tumors). In this population, situations of rapid clinical improvement known as the 'Lazarus effect' [32] are exceptional.
Conclusion
This study shows that one out of five hospitalized patients who die from metastatic cancers receive chemotherapy during their last month of life. Earle et al. [33] previously suggested to consider a rate of 10% of patients receiving chemotherapy in the last 14 days of life and a proportion of 2% of patients starting a new chemotherapy regimen during the last month before death to evaluate whether or not a healthcare system provides overly aggressive end-of-life cancer care. These criteria are useful as they encourage benchmark across countries and promote the overuse of potentially futile treatments as a quality-of-care issue. However, we believe that setting an a priori level of appropriate and inappropriate rate of chemotherapy near the end of life may hinder the aim of palliative care in oncology, i.e. to address the specific needs of each individual patient based not only on their illness trajectory or physical symptoms but also on their personal preferences and goals of care [34] . Rather than defining one-size-fits-all clinical standards, cancer care guidelines should therefore focus on shared decision-making and patient-physician communication, favoring personalized and tailored end-of-life decisions.
